1. d a c b
CD8
CD3
CD4
CD62L
HLA-DR
CD57
10%
85%
11%
76%
19%
60%
36%
66% 5% h e g f
Supplemental Figure 1.
Dasatinib patient with LGL lymphocytosis
Dasatinib patient without LGL lymphocytosis
Supplemental Figure 1. Immunophenotyping of peripheral blood (PB) cells.
Immunophenotyping of PB lymphocytes of a dasatinib patient with LGL lymphocytosis (Pt 6 in Table 1, panels a-d) and of a control patient (Pt 6 in Table 3, panels e-h). Panels a, b, e, and f show gated CD3-positive cells and panels c, d, g and h gated CD8-positive cells. Percentage of positive cells from the gated population is marked in the dot plots.